Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason J Luke

Showing results (71-80 of 185) with videos related to

Pageof 19
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 15, 2025
Beyond Checkpoint Inhibition: Keeping Therapeutic Options OpenUrvashi Mitbander Joshi, Jasmin Hundal, Jonaphine R Mata, et al.
Journal of the National Cancer Institute|August 10, 2014
Realizing the potential of plasma genotyping in an age of genotype-directed therapiesJason J Luke, Geoffrey R Oxnard, Cloud P Paweletz, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanomaStefani Spranger, Jason J Luke, Riyue Bao, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2016
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumorsJason J Luke, Patricia LoRusso, Geoffrey I Shapiro, et al.
Oncotarget|February 14, 2018
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancerShalin Shah, Kevin Wood, Brian Labadie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort studyLe Min, Frank Stephen Hodi, Anita Giobbie-Hurder, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastomaRiyue Bao, Stefani Spranger, Kyle Hernandez, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2024
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trialsConnor Lynch, Mark C Korpics, Rohan R Katipally, et al.
Journal for Immunotherapy of Cancer|March 22, 2025
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapyThomas U Marron, Jason J Luke, Brianna Hoffner, et al.
Critical Reviews in Oncology/Hematology|February 10, 2024
US physician perspective on the use of biomarker and ctDNA testing in patients with melanomaRachel A Fischer, Isabel Ryan, Kristine De La Torre, et al.
Pageof 19

Showing results (71-80 of 185) with videos related to

Sort By:
Pageof 19
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 15, 2025
Beyond Checkpoint Inhibition: Keeping Therapeutic Options OpenUrvashi Mitbander Joshi, Jasmin Hundal, Jonaphine R Mata, et al.
Journal of the National Cancer Institute|August 10, 2014
Realizing the potential of plasma genotyping in an age of genotype-directed therapiesJason J Luke, Geoffrey R Oxnard, Cloud P Paweletz, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanomaStefani Spranger, Jason J Luke, Riyue Bao, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2016
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumorsJason J Luke, Patricia LoRusso, Geoffrey I Shapiro, et al.
Oncotarget|February 14, 2018
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancerShalin Shah, Kevin Wood, Brian Labadie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort studyLe Min, Frank Stephen Hodi, Anita Giobbie-Hurder, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastomaRiyue Bao, Stefani Spranger, Kyle Hernandez, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2024
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trialsConnor Lynch, Mark C Korpics, Rohan R Katipally, et al.
Journal for Immunotherapy of Cancer|March 22, 2025
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapyThomas U Marron, Jason J Luke, Brianna Hoffner, et al.
Critical Reviews in Oncology/Hematology|February 10, 2024
US physician perspective on the use of biomarker and ctDNA testing in patients with melanomaRachel A Fischer, Isabel Ryan, Kristine De La Torre, et al.
Pageof 19